Monoclonal Antibodies
Showing 51 - 75 of 7,894
Hematological Malignancies Trial in Hangzhou (NK cells/Combined Monoclonal Antibodies)
Not yet recruiting
- Hematological Malignancies
- NK cells/Combined Monoclonal Antibodies
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Dec 8, 2020
Open-label, Uncontrolled, Non-Interventional, Retrospective
Recruiting
- Melanoma
- Lung Cancer
-
Edegem, BelgiumUniversitair Ziekenhuis Antwerpen
Apr 23, 2021
![](/image/sponsor/irccs_national_neurological_institute_"c_mondino"_foundation)
BIOmarkers of MIGraine:Proof of Concept Study Based on
Recruiting
- Migraine
-
Hamburg, Germany
- +2 more
Apr 27, 2021
HBV Trial in Paris (o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B)
Recruiting
- HBV
- o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
-
Paris, Ile De France, FranceValérie POURCHER
Feb 2, 2021
Corona Virus Disease Trial in United States (AZD7442, AZD8895 (clonal cell line material), AZD1061 (clonal cell line material))
Active, not recruiting
- Corona Virus Disease
- AZD7442
- +4 more
-
Anniston, Alabama
- +12 more
Aug 12, 2022
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)
Recruiting
- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia
- FT596
- +4 more
-
Chicago, Illinois
- +8 more
Jun 21, 2022
HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)
Completed
- HIV Antibodies
- VRC-HIVMAB091-00-AB
- EDP
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 8, 2022
NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1
Not yet recruiting
- Non-Small Cell Lung Cancer
- Capsulized Fecal Microbiota Transplant
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Aug 12, 2021
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma
Recruiting
- Multiple Myeloma
- Stem Cell Transplant
-
Firenze, Italy
- +1 more
Aug 19, 2021
Coronavirus Disease 2019 (COVID-19) Trial in United Kingdom, United States (AZD7442 (tixagevimab [AZD8895] + cilgavimab
Active, not recruiting
- Coronavirus Disease 2019 (COVID-19)
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
-
Birmingham, Alabama
- +15 more
Nov 7, 2022
Ebola Virus Disease Trial in Sankt-Peterburg (Gamezumab)
Recruiting
- Ebola Virus Disease
-
Sankt-Peterburg, Russian FederationResearch Institute of Influenza
Feb 17, 2021
Acute HIV Infection Trial in Brazil, Peru, United States (biological, other, drug)
Not yet recruiting
- Acute HIV Infection
- VRC07-523LS
- +3 more
-
Birmingham, Alabama
- +35 more
Jan 30, 2023
Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in
Not yet recruiting
- Non-Hodgkin Lymphoma, B-cell
- "novel" MAB (alone or in combination)
-
Viagrande, Catania, Italy
- +57 more
Aug 18, 2023
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
Completed
- Covid19
- Hematological Malignancy
-
Bari, Italy
- +13 more
Jun 21, 2022
HIV, Herpes Simplex Infections Trial in Providence (MB66, Placebo Film)
Completed
- HIV
- Herpes Simplex Infections
- MB66
- Placebo Film
-
Providence, Rhode IslandThe Miriam Hospital
Apr 19, 2021
Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)
Unknown status
- Lymphoma
- immunoscintigraphy
- technetium Tc 99m epratuzumab
-
Los Angeles, California
- +7 more
Aug 12, 2021
Prognostic Value of Protein IMP3 Expression in Cervical Cancer
Active, not recruiting
- Cervical Carcinoma
- immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
- (no location specified)
Jan 5, 2022
DLBCL Trial (R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide,hydroxyldaunorubicin,Vincristine,Prednisone)))
Not yet recruiting
- DLBCL
- (no location specified)
Apr 12, 2021
Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)
Not yet recruiting
- Human Immunodeficiency Virus
- 3BNC117-LS
- +2 more
-
New York, New York
- +2 more
Jul 12, 2022
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy Trial in Los Angeles (Clazakizumab)
Active, not recruiting
- Kidney Failure, Chronic
- +6 more
-
Los Angeles, CaliforniaNorko Ammerman
Mar 25, 2022
Ebola Virus Disease Trial in N'Zerekore (ansuvimab, Ervebo)
Not yet recruiting
- Ebola Virus Disease
- ansuvimab
- Ervebo
-
N'Zerekore, GuineaCentre de Traitement Ebola de N'Zerekore
Oct 14, 2021
Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy Trial in Los Angeles (Clazakizumab)
Active, not recruiting
- Antibody-mediated Rejection
- +5 more
-
Los Angeles, CaliforniaNorko Ammerman
Mar 25, 2022